Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
26 hedge funds and large institutions have $11.1M invested in Regulus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 1 closing their positions.
47,700% more call options, than puts
Call options by funds: $956K | Put options by funds: $2K
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
8% more funds holding
Funds holding: 24 → 26 (+2)
7.57% less ownership
Funds ownership: 55.58% → 48.01% (-7.6%)
20% less capital invested
Capital invested by funds: $13.8M → $11.1M (-$2.72M)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$66.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.27K |
| 4 |
Renaissance Technologies
New York
|
+$3.77K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$473 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$38K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$25.2K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$11.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.1K |
| 5 |
BlackRock
New York
|
-$1.45K |
RGLS Hedge Fund Activity: Q4 2022 in Review
26 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2022, worth a combined $11.1M — down 20% from $13.8M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new RGLS positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $66.8K. The largest seller was HRT Financial, exiting entirely with an estimated $38K sold.
- 26 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2022, up from 24 in Q3 2022.
- Funds reported $11.1M of Regulus Therapeutics stock for Q4 2022, down 20% quarter-over-quarter.
- 4 funds opened new Regulus Therapeutics positions in Q4 2022 and 1 closed out, a net change of +3 holders.
- The largest Regulus Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $66.8K added.
- The largest Regulus Therapeutics seller in Q4 2022 was HRT Financial, an estimated $38K sold.
Based on aggregated 13F filings for Q4 2022.